Vivodyne

Robotic, AI-enabled labs that grow functional human tissues to test drug candidates.

Website: https://www.vivodyne.com/

Cover Block

From the public record

Field Value
Name Vivodyne
Tagline Robotic, AI-enabled labs that grow functional human tissues to test drug candidates.
Headquarters San Francisco, USA [Technical.ly, April 2021]
Founded 2021 [Technical.ly, April 2021]
Stage Series A [STAT, May 2025]
Business model B2B [Technical.ly, April 2021]
Industry Deeptech
Technology Biotech / Life Sciences
Geography North America
Growth profile Venture Scale
Founding team Academic Spinout [Technical.ly, April 2021]
Funding label $50M+ [STAT, May 2025]
Total disclosed funding Approximately $82,000,000, based on disclosed rounds of $4,000,000 in April 2021, $38,000,000 in November 2023, and $40,000,000 in May 2025 [Technical.ly, April 2021] [Vivodyne, November 2023] [STAT, May 2025]

Links

From the public record

The Short Version

PUBLIC Vivodyne builds robotic, AI-enabled laboratories that grow functional human tissues and test drug candidates, a proposition that merits attention because investors are again backing platforms that promise more predictive preclinical data as pressure builds for alternatives to animal testing [Technical.ly, April 2021] [STAT, May 2025] [Endpoints News, retrieved 2026]. The company traces back to the University of Pennsylvania, where co-founder and CEO Andrei Georgescu developed the business with co-founder Dan Huh while working in Huh's BIOLines Lab, the source of the underlying organ-on-chip and human-tissue work [Vivodyne, November 2023] [Technical.ly, April 2021].

The product case is straightforward: Vivodyne says its platform combines lab-grown human organ tissues, microfluidics, robotics, and AI to run and analyze many drug experiments in parallel, with the intended advantage of generating earlier human-relevant evidence than conventional preclinical workflows [Vivodyne, November 2023] [Forbes, November 2023]. That differentiation still rests more on platform breadth and automation claims than on publicly disclosed customer outcomes, although TechCrunch reported in August 2026 that the company had opened what it called the world's largest "human data center" facility outside San Francisco, capable of running hundreds of thousands of experiments in parallel [TechCrunch, August 2026].

The founding team reads as technically credible for the problem at hand. Georgescu holds a Ph.D. in bioengineering from Penn, and Huh is a Penn professor and the director of the BIOLines Lab, which gives the company a clear academic-spinout lineage rather than a purely software-led origin story [Vivodyne, November 2023] [Technical.ly, April 2021].

On capitalization, Vivodyne has disclosed roughly $82 million across a $4 million seed round in 2021, a $38 million seed financing announced in November 2023, and a $40 million Series A reported in May 2025, with Kairos Ventures backing the first round and Khosla Ventures leading the later financings [Technical.ly, April 2021] [Vivodyne, November 2023] [STAT, May 2025]. The business model is B2B and appears oriented toward pharmaceutical and biotechnology customers, but the next 12 to 18 months likely turn on whether Vivodyne can translate facility scale and technical narrative into named partnerships, repeat commercial usage, and externally validated evidence that its tissue models improve drug-development decisions [Forbes, November 2023] [TechCrunch, August 2026].

Single-source, plausible -- Core company, team, and funding facts are corroborated by Technical.ly, Vivodyne, Forbes, and STAT, but several commercial and scale claims rely on company statements or single-source reporting.

Taxonomy Snapshot

Axis Value
Stage Series A
Business Model B2B
Industry / Vertical Deeptech
Technology Type Biotech / Life Sciences
Geography North America
Growth Profile Venture Scale
Founding Team Academic Spinout
Funding $50M+ total disclosed, approximately $82,000,000

The Company in Brief

PUBLIC

Vivodyne traces back to University of Pennsylvania research, then appears in the public record as a San Francisco-based company founded in 2021 [Crunchbase] [Vivodyne, November 2023]. The company describes itself as building robotic, AI-enabled laboratories that grow functional human tissues for drug testing, and its founding materials identify Andrei Georgescu and Dan Huh as the core founding team, with Georgescu developing the company while working in Huh's lab [Vivodyne, November 2023].

The milestone pattern is clear even if the early operating detail is still thin. Vivodyne raised a $4 million seed round in April 2021, then announced a much larger $38 million seed financing in November 2023, followed by a $40 million Series A reported in May 2025 [Vivodyne, November 2023]. By September 2026, the company said that financing was supporting a 23,000-square-foot fully robotic laboratory at Genesis Marina in South San Francisco, which lines up with its stated push to scale human-tissue experimentation rather than remain a lab-tool vendor at small volume [Vivodyne, September 2026].

Single-source, plausible -- This section relies primarily on Crunchbase and company materials, with chronology corroborated in part by Vivodyne's November 2023 and September 2026 publications.

What They Have Built

MIXED Product architecture and operating model

Vivodyne is building a preclinical testing platform around robotic, AI-enabled laboratories that grow functional human tissues and expose drug candidates to them, rather than relying only on conventional animal models or lower-throughput lab workflows [Technical.ly, April 2021]. Public descriptions are consistent on the core stack: lab-grown human organ tissues, microfluidics, robotics, and AI are combined to run and analyze experiments in parallel [Vivodyne, November 2023]. The plain-language point is straightforward. Vivodyne is selling a system for generating human-relevant experimental data before clinical trials, primarily for pharmaceutical and biotechnology customers [Technical.ly, April 2021] [Forbes, November 2023] [STAT, May 2025].

That framing matters because the company is not presented in public sources as a single assay, a software-only analytics layer, or a contract research shop in the narrow sense. The differentiator, at least in disclosed materials, is the integration of tissue engineering with automated experimentation and data analysis inside one lab workflow [Vivodyne, November 2023] [Forbes, November 2023]. Company materials say the system is intended to help drug developers identify ineffective or unsafe candidates earlier and improve the handoff from preclinical work to human trials, though that efficacy claim remains substantially company-sourced in the reviewed record [Vivodyne, November 2023].

MIXED Facility scale and public evidence of throughput

The most concrete recent product evidence is the company’s lab buildout. TechCrunch reported in August 2026 that Vivodyne had opened what it called the world’s largest "human data center" outside San Francisco, with systems growing multiple tissue types and running hundreds of thousands of experiments in parallel [TechCrunch, August 2026]. A separate company update ties the Series A financing to a 23,000-square-foot fully robotic laboratory at Genesis Marina in South San Francisco [Vivodyne, September 2026].

The cautious read is that public reporting supports real physical infrastructure and an automation-heavy operating model, but not yet a full independent benchmark of scientific performance across indications. Several secondary writeups describe the platform as generating data at industrial scale, and some cite named tissue counts or predictive accuracy figures, but those claims are not corroborated in the stronger source set provided here and should be treated as directional rather than established [TechCrunch, August 2026] [Forbes, November 2023] [Vivodyne, September 2026]. For investors, the technical question is less whether the lab exists, which public reporting supports, and more whether the resulting data consistently changes preclinical decision-making in ways that pharmaceutical buyers will pay for at scale.

Single-source, plausible -- Core product descriptions are corroborated by Technical.ly, Forbes, STAT, and Vivodyne materials; facility scale is supported by TechCrunch and Vivodyne, but performance claims remain only partially independently verified.

Market Size and Demand

PUBLIC

This market matters now because drug developers are under visible pressure to find preclinical models that are faster, more human-relevant, and less dependent on animal studies as AI-driven discovery pushes more candidates into the funnel [STAT, May 2025] [Endpoints News, retrieved 2026].

The public record does not provide a clean TAM, SAM, or SOM for Vivodyne itself, and no named third-party market report was supplied in the source set. The safer way to frame demand is through the workflow Vivodyne sits inside: preclinical drug testing and translational tools used by pharmaceutical and biotechnology companies before human trials [Technical.ly, April 2021] [Forbes, November 2023]. Vivodyne's pitch, according to company and media descriptions, is that lab-grown human tissues, microfluidics, robotics, and AI can generate earlier evidence on efficacy and safety than conventional preclinical approaches alone [Vivodyne, November 2023] [Technical.ly, April 2021]. That places the company in an adjacent spend pool tied to drug discovery services, organoid and organ-on-chip tools, and preclinical decision support rather than a standalone software category [STAT, May 2025] [Endpoints News, retrieved 2026].

Demand drivers are easier to verify than market size. Technical.ly described Vivodyne's earliest commercial target as drug developers that need functional human tissue models for candidate testing [Technical.ly, April 2021]. Forbes later reported that the company was already working with several companies on preclinical development and on investigating disappointing human trial results, which suggests demand on both the front end of candidate selection and the back end of trial troubleshooting [Forbes, November 2023]. TechCrunch in 2026 and STAT in 2025 both situate the company inside a broader push to improve the predictive value of preclinical research, especially where animal data may translate poorly to human biology [TechCrunch, August 2026] [STAT, May 2025].

The adjacent and substitute markets are broad, which cuts both ways. On one side are animal testing, contract research organizations, organoid platforms, organ-on-chip systems, and wet-lab automation providers, all of which can compete for the same R&D budget line depending on how a pharma buyer defines the problem [STAT, May 2025] [Technical.ly, April 2021]. On the other side are software-led AI drug discovery platforms that still need experimental data to validate targets and compounds, a dynamic that helps explain why Vivodyne describes its facility as a "human data center" and why media coverage frames its output as an input to model building rather than a replacement for biology itself [TechCrunch, August 2026] [Vivodyne, November 2023].

Regulatory and macro signals appear supportive, though the evidence here is still more directional than quantified. STAT's 2025 coverage explicitly tied Vivodyne's financing to alternatives to animal testing, and Endpoints later linked the company's vascularized tissue work to pressure from the FDA and NIH to develop substitutes for animal models [STAT, May 2025] [Endpoints News, retrieved 2026]. If that policy current continues, buyers may have stronger internal justification to trial human-tissue platforms earlier in development. The limiting factor is that regulation can encourage evaluation without guaranteeing procurement at scale, so commercial adoption will still turn on reproducibility, throughput, and whether results change program decisions in ways buyers can measure [TechCrunch, August 2026] [Forbes, November 2023].

Market frame Public evidence Relevance to Vivodyne
Preclinical drug testing workflow Vivodyne sells to pharmaceutical and biotechnology companies testing drug candidates before clinical trials [Technical.ly, April 2021] [Forbes, November 2023] Core budget context
Alternatives to animal testing Financing coverage ties the company to demand for organoid research and animal-testing alternatives [STAT, May 2025] Regulatory and scientific tailwind
Human-tissue experimental platforms Endpoints describes vascularized human tissues as part of the push for better preclinical models [Endpoints News, retrieved 2026] Direct product adjacency
AI drug discovery data infrastructure TechCrunch frames Vivodyne's facility as a source of large-scale human experimental data for AI-enabled drug development [TechCrunch, August 2026] Data-generation wedge

The table shows a market defined more by workflow convergence than by one clean category label. That is usually a sign of a large eventual spend pool, but it also means vendor comparisons inside a procurement process may be inconsistent from one buyer to the next.

Single-source, plausible -- Based mainly on named media coverage and company materials; no third-party market sizing report was provided in the source set.

Who Else Is Fighting for This

MIXED

Vivodyne appears to be positioning itself less as a point preclinical assay vendor and more as a scaled human-tissue experimentation platform, which places it against several different alternatives at once rather than one clean peer set [Technical.ly, April 2021] [Vivodyne, November 2023] [STAT, May 2025].

The first complication is that the public record here is thinner than the category narrative. The available sourcing supports Vivodyne's own position in the stack: a University of Pennsylvania spinout building robotic, AI-enabled laboratories that grow functional human tissues and test drug candidates in parallel, primarily for pharmaceutical and biotechnology customers [Technical.ly, April 2021] [Forbes, November 2023] [Vivodyne, November 2023]. What it does not support is a named, source-grounded peer list inside this report's evidence base, so the competitive map has to be drawn by segment rather than by an overconfident roster of direct comparables.

At the segment level, Vivodyne sits where organ-on-chip research, organoid and tissue-model platforms, preclinical CRO workflows, and animal-testing alternatives begin to overlap [Technical.ly, April 2021] [STAT, May 2025] [Endpoints News, retrieved 2026]. Incumbents in practice are not necessarily one startup class, but the established preclinical workflow itself: animal studies, conventional in vitro testing, and outsourced lab experimentation that drug developers already know how to buy and operationalize [STAT, May 2025] [Forbes, November 2023]. The challenger set, based on the sourced material, is better understood as companies and labs trying to generate earlier human-relevant data before clinical trials, especially as regulators and research agencies show more interest in alternatives to animal testing [STAT, May 2025] [Endpoints News, retrieved 2026]. Adjacent substitutes include AI-first drug discovery efforts that still depend on better wet-lab inputs, which is partly why Vivodyne has framed its lab as a "human data center" rather than only a tissue-testing service [TechCrunch, August 2026].

The clearest edge visible in public evidence is integration. Vivodyne is not just offering a tissue model, according to company and media descriptions, but a combined system of lab-grown tissues, microfluidics, robotics, and AI that can run large numbers of experiments in parallel [Vivodyne, November 2023] [Forbes, November 2023]. If that operating model works as described, the defensibility comes from accumulated experimental data, automation know-how, and the capital base required to stand up physical lab infrastructure at meaningful scale, including the 2026 South San Francisco facility the company said spans 23,000 square feet [TechCrunch, August 2026] [Vivodyne, September 2026]. That edge is promising but perishable. It becomes durable only if throughput converts into trusted customer outcomes, repeat programs, and a data asset that improves faster than rivals can replicate with their own tissue systems and automation budgets.

The exposure is also fairly clear from the same evidence. Vivodyne has raised substantial disclosed capital, about $82 million across seed and Series A rounds, but it is still competing from a category that asks customers to change preclinical decision processes rather than merely add software to an existing stack [Technical.ly, April 2021] [Vivodyne, November 2023] [STAT, May 2025]. The company has said it works with several companies and multiple major pharmaceutical groups, yet the public record reviewed here does not name those customers or show public benchmark studies against specific rival platforms [Forbes, November 2023] [TechCrunch, August 2026]. That leaves an opening for better-entrenched substitutes: incumbent CRO relationships, animal-study workflows that remain standard in many programs, and any tissue-platform competitor with clearer published validation or channel access. Put plainly, Vivodyne may own an ambitious technical position, but it does not yet publicly own the buying channel.

The most plausible 18-month competitive scenario is therefore conditional. Vivodyne is the likely winner if the category shifts from proof-of-concept interest to scaled procurement around earlier human-relevant data, because its combination of automation, tissue growth, and facility buildout suggests it is trying to meet volume and workflow requirements rather than sell bespoke science projects [Vivodyne, November 2023] [TechCrunch, August 2026]. The likely loser if that transition stalls is not a named startup in this evidence base, but the broader class of new preclinical platform vendors whose commercial case depends on replacing incumbent animal and lab-testing workflows faster than biopharma buyers are willing to change them [STAT, May 2025] [Endpoints News, retrieved 2026]. On current public evidence, the competitive question is less whether Vivodyne has an interesting product than whether it can convert technical differentiation into category-setting commercial evidence before adjacent alternatives close the gap.

Single-source, plausible -- Based primarily on company materials and independent coverage from Technical.ly, Forbes, STAT, TechCrunch, and Endpoints News, with no named competitor set confirmed in the provided public sources.

Opportunity

Upside case

PUBLIC The prize here is not a better preclinical tool but a credible shot at becoming core infrastructure for how drug developers generate human-relevant evidence before and around clinical trials, a budget line that is far larger and stickier than a single assay or software seat if the platform proves predictive at scale [Technical.ly, April 2021] [Forbes, November 2023] [STAT, May 2025].

The clearest upside is that Vivodyne becomes a default external platform for human-tissue testing across pharma R&D workflows, starting in preclinical candidate selection and expanding into trial-supporting studies for assets that need more human-relevant data [Technical.ly, April 2021] [Forbes, November 2023] [TechCrunch, August 2026]. That outcome is reachable, not merely aspirational, because three ingredients are already visible in public reporting: a technical stack that combines human tissues, microfluidics, robotics, and AI in one system; repeat venture backing from specialist investors across seed and Series A financings; and evidence that the company is already working with several drug-development customers, even if those customers remain unnamed [Vivodyne, November 2023] [Forbes, November 2023] [STAT, May 2025]. The August 2026 opening of a 23,000-square-foot robotic facility in South San Francisco adds a fourth ingredient, physical capacity, which matters in this category because throughput is part of the product, not just a back-office detail [TechCrunch, August 2026] [Vivodyne, September 2026].

A reasonable way to frame the growth paths is to separate service-led adoption from infrastructure-like adoption. The first asks whether pharma teams will pay for better preclinical answers. The second asks whether those answers can become embedded deeply enough to shape portfolio decisions, rescue programs, and eventually the training data used across therapeutic development [Forbes, November 2023] [TechCrunch, August 2026].

Scenario What happens Catalyst Why it's plausible
Pharma workflow wedge Vivodyne becomes a repeat vendor to large biopharma teams for preclinical candidate testing and mechanism validation, with programs broadening from one tissue or indication to multiple internal portfolios More disclosed evidence that major pharma users are expanding from pilot work into recurring programmatic use [Forbes, November 2023] [TechCrunch, August 2026] Public reporting already says the company works with several companies on preclinical development and with multiple major pharmaceutical companies, which suggests initial commercial pull exists even without named logos [Forbes, November 2023] [TechCrunch, August 2026]
Human-data infrastructure The South San Francisco facility turns Vivodyne from a boutique testing provider into a scaled data-generation platform that can run very large parallel experiment volumes for many customers and modalities Utilization of the 23,000-square-foot robotic lab and further evidence that hundreds of thousands of experiments can be run in parallel [TechCrunch, August 2026] [Vivodyne, September 2026] TechCrunch reported the company opened what it called the world's largest human data center facility, and the company has consistently positioned autonomous experimentation capacity as central to the offering [TechCrunch, August 2026] [Vivodyne, November 2023]
Clinical rescue and development support Vivodyne extends from preclinical screening into helping drug developers interpret disappointing trial signals, improve target selection, or support Phase I/II decisions with additional human-tissue data One or more publicly described case studies showing use beyond early discovery, especially around underperforming assets or trial design [Forbes, November 2023] [Longevity.Technology] Forbes reported work on investigating disappointing human-trial results, and company materials describe support across target validation, lead optimization, and trial design, though the latter remains company-led evidence [Forbes, November 2023] [Vivodyne, retrieved 2026]

The compounding mechanism is straightforward if the underlying biology holds up. More customer programs should produce more experimental data across tissues, compounds, and disease contexts; more data should improve the value of the analytical layer and make the next customer's study design faster or more informative; and higher facility utilization should spread fixed robotics and lab overhead across a larger base of work [Vivodyne, November 2023] [TechCrunch, August 2026]. In that setup, every new pharma relationship does double duty, bringing revenue and expanding the data asset that can make future engagements more defensible. The public signs that this flywheel may be starting are still early but real: the company has progressed from a six-person team planning post-seed expansion in 2021 to 43 employees by March 2026, while also raising capital specifically around scaling its human-tissue platform and physical lab footprint [Technical.ly, April 2021] [Revelio Labs, March 2026] [STAT, May 2025].

The size of the win depends on whether investors underwrite Vivodyne as a tools company, a platform company, or eventually a data-infrastructure company for drug development. Public sources in this record do not provide a market-size benchmark or a tightly matched public comparable, so the safest way to express upside is through revenue quality rather than headline TAM. If scenario two plays out and the company becomes a scaled, recurring platform for major biopharma R&D budgets, the business could plausibly support infrastructure-style enterprise value rather than project-by-project services value, because it would sit upstream of candidate selection and downstream of human-relevant evidence generation [Forbes, November 2023] [STAT, May 2025] [TechCrunch, August 2026]. That would place the outcome in the category of multibillion-dollar platform companies in life-science tools and data infrastructure, not as a forecast, but as a scenario contingent on proving that its human-tissue outputs are predictive enough to influence expensive development decisions at repeatable scale [Technical.ly, April 2021] [Vivodyne, November 2023] [Endpoints News, retrieved 2026].

Single-source, plausible -- Built primarily from Technical.ly, Forbes, STAT, TechCrunch, and company materials; several core commercial and performance claims remain only partially corroborated in public sources.

Sources

From the public record

  1. [Technical.ly, April 2021] Vivodyne is a University of Pennsylvania spinout developing robotic, AI-enabled laboratories that grow functional human tissues and test drug candidates on them | https://technical.ly/startups/vivodyne-testing-raise/

  2. [STAT, May 2025] Vivodyne raises $40 million for organoid research | https://www.statnews.com/2025/05/29/animal-testing-alternatives-biotech-vivodyne-raises-40-million-for-organoid-research/

  3. [Vivodyne, November 2023] Vivodyne announces $38 million seed financing led by Khosla Ventures | https://www.vivodyne.com/blog/vivodyne-announces-38-million-seed-financing-led-by-khosla-ventures

  4. [Endpoints News, retrieved 2026] Vivodyne grows vascularized human tissues to screen drugs as the FDA and NIH push alternatives to animal testing | https://endpts.com/

  5. [Forbes, November 2023] This Startup Raised $38 Million To Fill One Of The Biggest Gaps In Drug Discovery | https://www.forbes.com/sites/alexknapp/2023/11/22/this-startup-raised-38-million-to-fill-one-of-the-biggest-gaps-in-drug-discovery/

  6. [TechCrunch, August 2026] AI isn’t close to curing cancer, this startup says it knows what it will take | https://techcrunch.com/2026/08/19/ai-isnt-close-to-curing-cancer-this-startup-says-it-knows-what-it-will-take/

  7. [Crunchbase] Vivodyne - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/vivodyne

  8. [Vivodyne, September 2026] Vivodyne blog | https://www.vivodyne.com/blog

  9. [Longevity.Technology] Longevity.Technology | https://longevity.technology/

Articles about Vivodyne

View on Startuply.vc